Cell Marque Portfolio

Arginase-1 (SP156)

Rabbit Monoclonal


Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver accounting for an estimated 70%-85% of total liver cancers worldwide1,2. While the highest liver cancer rates are found in East and Southeast Asia and sub-Saharan Africa, the incidence is increasing in the West due to the burden of chronic hepatitis C infection and steatohepatitis attributed to the obesity epidemic1,3. Although advancements in diagnostic imaging modalities and refined methods of clinical investigation have obviated the need for tissue diagnosis in some cases4,5, fine needle aspiration (FNA) biopsy remains the procedure of choice in the assessment and diagnosis of focal liver nodules and masses2. Unfortunately, diagnostic pitfalls exist in the morphologic distinction of HCC from other hepatocellular and non-hepatocellular mass lesions. Of note, the morphologic distinction of regenerative cirrhotic nodules, hepatic adenoma, and focal nodular hyperplasia from well-differentiated HCC presents a diagnostic challenge, particularly in small biopsies with limited sampling. Similarly, cases of metastatic carcinoma and other benign and malignant non-hepatocellular mimics are well documented and can be problematic4-7. In difficult or equivocal cases, the application of immunohistochemical (IHC) panels has been shown to aid in the distinction of benign and malignant liver lesions4-9. In particular, the application of CD10, polyclonal carcinoembryonic antigen, alpha-fetoprotein, HepPar-1, and glypican-3 (GPC-3) IHC has proven valuable in liver biopsy and FNA cytology specimens5-10. IHC staining for HepPar-1, a mitochondrial urea cycle antigen, has demonstrated high sensitivity and specificity in the distinction between metastatic carcinoma and HCC but is also expressed in benign hepatocellular lesions8,9. In contrast, GPC-3, a heparin sulphate proteoglycan expressed at high levels in HCC, has shown high specificity with suboptimal sensitivity in the diagnosis of HCC when used in isolation. Arginase-1 is a key urea cycle metalloenzyme that has demonstrated expression in normal human liver with a high degree of specificity11,12. In sections of normal liver, anti-arginase-1 produced strong, diffuse cytoplasmic reactivity in all hepatocytes throughout the lobule. In a small percentage of cases, patchy nuclear reactivity is also evident in hepatocytes along with the strong cytoplasmic reactivity. There is no reactivity in bile duct epithelial cells, sinusoidal endothelial cells, Kupffer cells, or vascular endothelial cells. In sections of HCC, anti-arginase-1 produces either cytoplasmic or cytoplasmic plus nuclear reactivity.

Specialties: Anatomic Pathology Gastrointestinal (GI) Pathology

Specifications


  • Reactivity: paraffin
  • Visualization: cytoplasmic, nuclear
  • Control: normal liver, hepatocellular carcinoma
  • Isotype: IgG
  • Dilution Range: 1:25-1:100*

Protocols


  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/Perm Red
  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/DAB
  • Ventana OptiView
    OV/CC1(32min)/16min @ 37°C
  • Ventana ultraView
    UV/CC1S/32min @ 37°C
  • Leica Bond
    Protocol F: ER1/20

Package Inserts


IFU SDS

References


  1. Jemal A, et al. CA Cancer J Clin. 2011; 61:69- 90.
  2. Linda DF. Philadelphia, PA: W.B. Saunders. 2009; 1291-325.
  3. El-Serag HB. Clin Liver Dis. 2001; 5:87-107.
  4. Wee A. Cytojournal. 2005; 2:7.
  5. Wee A. Cytopathology. 2011; 22:287-305.
  6. Niemann TH, et al. Cancer. 1999; 87:295-298.
  7. Onofre AS, et al. Cancer. 2007; 111:259-268.
  8. Nassar A, et al. Diagnostic Cytopathology. 2009; 37:629-635.
  9. Zimmerman RL, et al. Cancer. 2001; 93:288-291.
  10. Zhu ZW, et al. Gut. 2001; 48:558-564.
  11. Multhaupt H, et al. Histochemistry. 1987; 87:465-470.
  12. Sekine S, et al. J Pathol. 2009; 219:365-372.
  13. Yan BC, et al. Am J SurgPathol. 2010; 34:1147-1154.
  14. McKnight, R et al. Cancer Cytopathology. 2012; 120:223-9.

Last updated: 2017-05-24 08:46:09

Arginase-1
Arginase-1 (SP156) on liver, cirrhosis.

Mouse over to zoom, use scroll wheel to zoom in/out

Tap image once to activate zoom lens


Specifications


  • Reactivity: paraffin
  • Visualization: cytoplasmic, nuclear
  • Control: normal liver, hepatocellular carcinoma
  • Isotype: IgG
  • Dilution Range: 1:25-1:100*

Protocols


  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/Perm Red
  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/DAB
  • Ventana OptiView
    OV/CC1(32min)/16min @ 37°C
  • Ventana ultraView
    UV/CC1S/32min @ 37°C
  • Leica Bond
    Protocol F: ER1/20

References


  1. Jemal A, et al. CA Cancer J Clin. 2011; 61:69- 90.
  2. Linda DF. Philadelphia, PA: W.B. Saunders. 2009; 1291-325.
  3. El-Serag HB. Clin Liver Dis. 2001; 5:87-107.
  4. Wee A. Cytojournal. 2005; 2:7.
  5. Wee A. Cytopathology. 2011; 22:287-305.
  6. Niemann TH, et al. Cancer. 1999; 87:295-298.
  7. Onofre AS, et al. Cancer. 2007; 111:259-268.
  8. Nassar A, et al. Diagnostic Cytopathology. 2009; 37:629-635.
  9. Zimmerman RL, et al. Cancer. 2001; 93:288-291.
  10. Zhu ZW, et al. Gut. 2001; 48:558-564.
  11. Multhaupt H, et al. Histochemistry. 1987; 87:465-470.
  12. Sekine S, et al. J Pathol. 2009; 219:365-372.
  13. Yan BC, et al. Am J SurgPathol. 2010; 34:1147-1154.
  14. McKnight, R et al. Cancer Cytopathology. 2012; 120:223-9.

Package Inserts

Select revision:



Ordering Information

For in vitro diagnostic (IVD) use in USA

25 mL predilute 380R-10
0.1 mL concentrate 380R-14
0.5 mL concentrate 380R-15
1 mL concentrate 380R-16
1 mL predilute 380R-17
7 mL predilute 380R-18

For in vitro diagnostic (IVD) use in Canada

25 mL predilute 380R-10
0.1 mL concentrate 380R-14
0.5 mL concentrate 380R-15
1 mL concentrate 380R-16
1 mL predilute 380R-17
7 mL predilute 380R-18

For in vitro diagnostic (IVD) use in Europe

25 mL predilute 380R-10
0.1 mL concentrate 380R-14
0.5 mL concentrate 380R-15
1 mL concentrate 380R-16
1 mL predilute 380R-17
7 mL predilute 380R-18

For research use only (RUO) in Japan

25 mL predilute 380R-10-RUO
0.1 mL concentrate 380R-14-RUO
0.5 mL concentrate 380R-15-RUO
1 mL concentrate 380R-16-RUO
1 mL predilute 380R-17-RUO
7 mL predilute 380R-18-RUO

 

For more information about this product in your area, contact us by clicking the button below.

Specifications


  • Reactivity: paraffin
  • Visualization: cytoplasmic, nuclear
  • Control: normal liver, hepatocellular carcinoma
  • Isotype: IgG
  • Dilution Range: 1:25-1:100*

Protocols


  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/Perm Red
  • Cell Marque HiDef
    T-PC/10-30minAb/HiDef/DAB
  • Ventana OptiView
    OV/CC1(32min)/16min @ 37°C
  • Ventana ultraView
    UV/CC1S/32min @ 37°C
  • Leica Bond
    Protocol F: ER1/20

Download Package Insert

Select revision:


Keycode Specific Package Insert

Keycode:
Select prefix.
Please verify your keycode and try again. If problems presist contact Customer Service
Enter keycode.
Please verify your keycode and try again. If problems presist contact Customer Service

Some products may have special labeling requirements in the United States.

Are you located in the U.S.?


*Note: IFUs with the prefix RUO or ASR are only available for download in English.



Click here to learn about keycodes

Download SDS

References


  1. Jemal A, et al. CA Cancer J Clin. 2011; 61:69- 90.
  2. Linda DF. Philadelphia, PA: W.B. Saunders. 2009; 1291-325.
  3. El-Serag HB. Clin Liver Dis. 2001; 5:87-107.
  4. Wee A. Cytojournal. 2005; 2:7.
  5. Wee A. Cytopathology. 2011; 22:287-305.
  6. Niemann TH, et al. Cancer. 1999; 87:295-298.
  7. Onofre AS, et al. Cancer. 2007; 111:259-268.
  8. Nassar A, et al. Diagnostic Cytopathology. 2009; 37:629-635.
  9. Zimmerman RL, et al. Cancer. 2001; 93:288-291.
  10. Zhu ZW, et al. Gut. 2001; 48:558-564.
  11. Multhaupt H, et al. Histochemistry. 1987; 87:465-470.
  12. Sekine S, et al. J Pathol. 2009; 219:365-372.
  13. Yan BC, et al. Am J SurgPathol. 2010; 34:1147-1154.
  14. McKnight, R et al. Cancer Cytopathology. 2012; 120:223-9.
Request More Information